Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: sam who wrote (5011)	7/29/1998 10:05:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 6136

sam: Do you mean the rit/crix (400/400) studies and the ilk? Allows for bid, consumption of crix with food, and a reduced frequency (postulated) of kidney sludge. Sounds like nelf alone. aside.... I attended the Informed Investor forum last Sunday in San Francisco. One of the keynote speakers was Von Emster of the Franklin Biotech Discovery Fund. He went out of his way to state that he had sold AGPH, that he didn't feel it wise to spin out oncology. More than meets the eye here, and he referred to loading up on VRTX and their "second or third generation PI". I kid you not. So, we now know that this mutual fund has been selling recently. We also know that a decent fraction of shares short have been covered in the past reporting period and that "days to cover" dropped from 20.3 to 8.4. Some with short positions are exiting. I propose that overt selling and buying-to-cover has been and will be coordinated. Rick